Mitomycin as a modulator of irinotecan anticancer activity

Miguel A Villalona-Calero; Jill M Kolesar

Back

Mitomycin as a modulator of irinotecan anticancer activity

Journal article

Peer reviewed

Mitomycin as a modulator of irinotecan anticancer activity

Miguel A Villalona-Calero and Jill M Kolesar

Oncology (Williston Park, N.Y.), Vol.16(8 Suppl 7), pp.21-25

08/01/2002

PMID: 12199629

View Online

Abstract

Irinotecan and mitomycin (Mutamycin) possess significant single-agent activity against several tumor types, and mitomycin activates topoisomerase I, the cellular target of irinotecan. We conducted a phase I dose-escalation study of irinotecan and mitomycin in 37 evaluable patients with solid tumors. Antitumor responses included 2 complete responses, 5 partial responses, 10 minor responses, and a CA 19-9 tumor marker response. Responders included 14 patients previously treated with chemotherapy for metastatic disease. No pharmacokinetic interaction between mitomycin and irinotecan was apparent when these agents were given 24 hours apart. Responders (complete and partial responses) demonstrated the largest topoisomerase I induction 24 hours following mitomycin infusion. In addition, since maximum topoisomerase I up-regulation was reached 24 hours after administration of mitomycin, a delay in the administration of irinotecan after mitomycin appeared justified. Based on these encouraging phase I data, phase II clinical trials in breast and esophageal/gastroesophageal junction adenocarcinomas at the recommended doses and schedule are under way.

Antineoplastic Combined Chemotherapy Protocols - administration & dosage

Antineoplastic Combined Chemotherapy Protocols - adverse effects

Biopsy, Needle

Camptothecin - administration & dosage

Camptothecin - adverse effects

Camptothecin - analogs & derivatives

Dose-Response Relationship, Drug

Drug Administration Schedule

Drug Synergism

Female

Humans

Male

Maximum Tolerated Dose

Mitomycin - administration & dosage

Mitomycin - adverse effects

Neoplasm Staging

Neoplasms - drug therapy

Neoplasms - mortality

Neoplasms - pathology

Patient Selection

Prognosis

Survival Analysis

Treatment Outcome

Details

Title: Subtitle: Mitomycin as a modulator of irinotecan anticancer activity
Creators: Miguel A Villalona-Calero - The Ohio State University
Jill M Kolesar
Resource Type: Journal article
Publication Details: Oncology (Williston Park, N.Y.), Vol.16(8 Suppl 7), pp.21-25
PMID: 12199629
ISSN: 0890-9091
eISSN: 2767-7389
Language: English
Date published: 08/01/2002
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984696545302771

Metrics

1 Record Views

14 Times Cited - Web of Science